MedTrace Logo

FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)

NCT01071122 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 365

Last updated 2014-01-27

No results posted yet for this study

Summary

To determine whether the combination of nifedipine GITS and valsartan is more effective in reducing central blood pressure than nifedipine GITS or valsartan alone, and to determine whether nifedipine GITS is comparable to valsartan

Conditions

Interventions

DRUG

Nifedipine (Adalat, BAYA1040) and Valsartan

Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily

DRUG

Nifedipine (Adalat, BAYA1040)

Nifedipine 60mg, Once daily

DRUG

Valsartan

Valsartan 160mg, Once daily

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01071122 on ClinicalTrials.gov